Anavex Life Sciences Corp (AVXL)

[falconer66a]

After blarcamesine, even better: Anavex 3-71.

Dr. M said that they are planning a 3-71 trial for AD.

This is good news. In animal model tests, Anavex 3-71 equals or exceeds the favorable outcomes of blarcamesine (Anavex 2-73).

Interestingly (well, importantly), Anavex 3-71 requires far lower dosages to function. In preclinical murine (lab rodent) tests dosages were in micrograms, not the milligrams required for blarcamesine. This will minimize production costs for commercial sales of Anavex 3-71. A microgram is a thousandth of a milligram.

The preclinical murine data reveal therapeutic outcomes equal or better than blarcamesine. The fact the Missling has suggested new trials of Anavex 3-71 in humans with Alzheimer’s strongly suggests that he has additional supporting data. He’s not proposing the new trials because blarcamesine is a failure. Apparently, it’s just not as good as Anavex 3-71. We’ll have to wait for more information, both murine and human, but Anavex 3-71 may simply work better than blarcamesine; stronger, perhaps even faster, more enduring symptomatic reversals. It may also prove to be a better Alzheimer’s prophylactic.

As always with matters Anavex, let the trials begin.